Literature DB >> 28941564

Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology.

Mary Elizabeth Davis, Jasmine H Francis.   

Abstract

OBJECTIVE: To discuss interprofessional collaboration between the primary oncology clinicians and specialists in the management of immune-related ocular toxicities. DATA SOURCES: Peer-reviewed articles, case reports and systematic reviews.
CONCLUSION: Accurate ophthalmologic assessment is critical for the prevention and treatment of ocular toxicities associated with immunotherapy. IMPLICATIONS FOR NURSING PRACTICE: Oncology nurses play a key role in early identification and management of ocular symptoms from immunotherapy; early referral to ophthalmic specialists can enhance recovery and preserve sight.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  checkpoint inhibitor; eye; immunotherapy; interprofessional collaboration; management; toxicity

Mesh:

Substances:

Year:  2017        PMID: 28941564     DOI: 10.1016/j.soncn.2017.08.003

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  4 in total

1.  Diagnosis and Management of Rare Immune-Related Adverse Events.

Authors:  Sara R Schoenfeld; Mary E Aronow; Rebecca Karp Leaf; Michael Dougan; Kerry L Reynolds
Journal:  Oncologist       Date:  2019-11-06

Review 2.  Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

Authors:  Yu-Wen Zhou; Qian Xu; Yan Wang; Ruo-Lan Xia; Ji-Yan Liu; Xue-Lei Ma
Journal:  Int J Ophthalmol       Date:  2022-04-18       Impact factor: 1.779

3.  Isolated Abducens Nerve Palsy Following Pembrolizumab.

Authors:  Korey A Jaben; Jasmine H Francis; Alexander N Shoushtari; David H Abramson
Journal:  Neuroophthalmology       Date:  2019-01-16

Review 4.  Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.

Authors:  Lin Zhou; Xin Wei
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.